Key Takeaways:
MEDCAPTAIN (02041.HK) launched its Hong Kong IPO at HKD15.42 per share, seeking about HKD496 million in net proceeds from a 38.9 million-share global offering.
The company will offer 38.9106 million H shares, with the Hong Kong public offering accounting for about 10 percent and the international placing about 90 percent, according to the company's announcement. Each board lot is 100 shares, requiring an entry fee of about HKD1,557.55. The company did not disclose its oversubscription ratio, cornerstone investors, or a breakdown of how the proceeds will be used.
The offer period runs from today (28 August) through next Wednesday (2 September), with the company expecting to list on the Main Board on 7 September. The 10 percent retail allocation is the standard minimum for Hong Kong public offerings, with the remaining 90 percent reserved for institutional investors through the international placing.
The pricing sets an implied valuation that first-day trading on 7 September will test, as institutional demand for the shares becomes clear. The listing follows UBS raising its price target on Hong Kong Exchanges & Clearing (00388.HK) to HKD450 while reiterating a Neutral rating, a backdrop of steady interest in Hong Kong listings. Investors will watch the closing of the offer on 2 September for signs of demand before the shares begin trading, with the deal's final allocation and any clawback triggered by retail oversubscription to be confirmed at that point.
This article is for informational purposes only and does not constitute investment advice.
